Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
Latest Information Update: 24 Jun 2022
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms STAR-RA; STAR-RA-Cancer
- 17 Jun 2022 Status changed from active, no longer recruiting to completed.
- 29 May 2022 Results published in the Arthritis and Rheumatology
- 09 Nov 2021 Results assessing safety (risk of malignancy) of tofacitinib in patients with rheumatoid arthritis in real-world settings, presented at the ACR Convergence 2021.